Guoyuan Securities maintains a buy rating on Entrepreneurship Huikang, and comments on the 2021 annual report: medical and health informatization leads the growth, and cloud-based products are released one after another.


Full Data

?
UNLOCK DATA

Subscribe & Access the Best Data and Intelligence on the Chinese Stock Markets


Join Now!

Need this critical market data?

Access thousands of market events, data points, and news articles!


Already have an account?
Login




Related Data